Regulatory T cells (Tregs) play a crucial role in the control of the initiation and progression of type 1 diabetes (T1D). Various immunological interventions including those to ex vivo expansion Tregs transfer, in vivo induction of peripherally derived Treg (pTreg) have been considered as promising approaches for T1D therapy. In this study, we developed a novel tolerogenic vaccine using four autoantigenic peptides of isletderived with cyclosporine A (CsA) as the pTreg inducer, designated as GAD-IN+CsA. This vaccine immunized into prediabetic NOD mice subcutaneously could induce IL-10 and TGF-β expressing pTregs and lead to suppressing autoreactive T cells responses, resulting in the prevention of T1D in these animals. Furthermore, we demonstrated that CsA with autoantigenic peptides modulates dendritic cells (DCs) to become immature IL-10 hi CD40
Introduction
The prevalence of Type 1 diabetes (T1D) is increasing globally among young children at a higher rate in developed countries over developing countries.
1 T1D is a severe chronic autoimmune disease characterized by progressive loss of pancreatic β cells resulting in deficient insulin production and hyperglycemia. T1D-related autoimmune activation has been highly suspected a malfunction of immunotolerance. Bold evidence has demonstrated that the balance of pathogenic and immune regulatory pathways underlies disease progression in T1D. 2, 3 Particularly, defective regulatory T cells (Tregs) caused uncontrolled autoimmune activation plays a pivotal role in the development of T1D. 4, 5 Re-enforcing the immune regulation by suppressing autoimmunity with various immunosuppressants has been tried in clinical settings only achieved short-term beneficial effects, suggesting temporary suppression on autoimmunity but not cure. Once withdraw of such drug, the disease progression develops as usual. Anti-CD3 or -CD4 antibody treatment in patients with T1D has also failed, which added another example to this category. Therefore, alternatives with more targeted approaches are urgently needed. One of such is to isolate polyclonal Tregs from patient with T1D, expanded into millions in vitro, and transferring back to the same patient. 6 However, this approach has been approved to have problems with short-lived and uncertainty of these Tregs after transfusion into a patient. 7 Over the past few years, there has been an increasing interest in the induction of Tregs for immunotherapeutic treatment against autoimmune diseases including T1D. For instance, anti-CD3 monoclonal antibody treatment has been demonstrated to induce adaptive Tregs and remission of the disease since this antibody directly interacts with T cells, interrupts its activation, and tips T effector cells (Teffs) toward more Tregs. 8, 9 Unfortunately, such a strategy fails to translate into clinical benefit for patients with T1D but raises more concerns on the consequence of biased systemic immunity. Other approaches aim to foster Tregs through inducing tolerogenic dendritic cells (tolDCs) in vitro or in vivo. [10] [11] [12] Due to DCs have an essential function in initiating adaptive immune responses by recognizing, processing, and presenting specific antigens to T cells, it could highly activate Teffs and lead to the effective elimination of pathogens with full maturation status through up-regulating costimulatory molecules (e.g., CD40, CD86, CD80). Conversely, a DC encountering self-antigens could become a tolerogenic status resulting in an immune tolerance response against auto-reactive T cells via induction of pTregs. The latter mechanism has become a novel immunotherapeutic strategy to develop multiple laboratory methods against autoimmune diseases. The induction of pTregs fostered by tolDCs involves mechanisms largely unknown although some of the crucial factors having been demonstrated in an association during such induction, which includes the presence of anti-inflammatory cytokines (e.g., IL-10 or TGF-β) in local micro-environment as a tolerogenic environment and immature DCs when interacting with naïve T cells.
To explore the induction of immune tolerance, particularly antigen-specific pTregs, influencing the micro-environment of DC-T interaction during an antigen processing and presentation with a minuscule amount of immunosuppressant could alter the outcome toward pTregs induction. This can be achieved through the administration of antigen with dexamethasone or cyclosporine A (CsA) subcutaneously as a "tolerogenic" vaccine as reported previously in our lab. 15, 16 Since T1D is an autoimmune disease with aberrant activation of Teffs and deficiency of Tregs, we hypothesized that autoantigens derived from the islet of pancreas formulated with CsA might be able to induce antigen-specific pTregs and potentiate immune tolerance against T1D in prediabetic NOD mice. In this study, we demonstrated that the formulated autoantigenic islet peptides (GAD65 206-220 , GAD65 536-550 , Insulin B 9-23 , and C 17 -A 1 ) with CsA applied as a tolerogenic vaccine prevented the development of T1D in prediabetic NOD mice. This tolerogenic vaccine modulated DCs to acquire tolerogenic phenotypes and induced a higher level of pTregs, which could be a promising therapeutic approach for T1D.
Results

GAD-IN plus CsA vaccine induces the tolerogenic response in mice
Islet-derived peptides have been demonstrated as autoantigens associated with T cell activation in patients with T1D, suitable to develop tolerogenic vaccines. Here, we chose four islet-derived peptides (GAD65 206-220 , GAD65 536-550 , Insulin B [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] , and Insulin C 17 -A 1 ), combined with CsA as GAD-IN +CsA vaccine. In detail, we mixed either 10, 20, or 40 μg of peptides together and formulated with 10 μg of CsA, whereas 40 μ of mixed multi-peptides alone, 10 μ of CsA alone or vehicle served as controls. The formulated GAD-IN+CsA vaccine was immunized subcutaneously into female BALB/c mice three immunizations on days 0, 6, and 12. The frequency of CD4 + CD25 +
Foxp3
+ pTregs was evaluated from the draining lymph node after vaccinations and showed an increase significantly in the groups immunized with 10, 20, and 40 μg of GAD-IN+CsA vaccine, while the 20 μg of GAD-IN+10 μ CsA regimen had achieved the highest level over other groups ( Figure 1 ).
To demonstrate effectiveness to induce pTregs by the GADIN+CsA vaccine, 6-8 weeks old male NOD mice were administrated five times with 50 mg/ml STZ each day, [17] [18] [19] and then given the 20 μg GAD-IN+CsA vaccine subcutaneously on days 0, 6, and 12 ( Figure 1a ). Twenty-four hours later after the last vaccination, a higher frequency of CD4 + CD25 +
+ pTregs was observed in the pancreatic lymph node of that 20 μg GADIN+CsA immunized NOD mice compared to that of the multiple-peptides mix without CsA, CsA alone or vehicle (Figure 1b) . The expression levels of IL-10 and TGF-β in these induced Foxp3 + p Tregs were elevated after GAD-IN+CsA vaccinations, indicating that these pTregs may bear suppressive function (Figure 1c and d) . In addition, the increased expression of ki67 in pTreg was detected after GAD-IN autoantigenic peptides stimulation in vitro, suggesting the antigen-specific pTreg were engendered after GAD-IN+CsA vaccination (Figure 1e ). In contrast, expression levels of IFN-γ, TNF-α, and IL-2 of antigen-specific CD4 + Teff cells were significantly decreased in the GAD-IN+CsA immunized animals at the same period compared with the control treatments (Figure 1f-i) . The multipeptides without CsA induced higher levels of these inflammatory cytokines in the activated CD4 + Teff cells. The result indicated that these autoreactive pathogenic Teffs were suppressed in the group immunized with the GAD-IN+CsA vaccine by not in the other groups, and the peptides alone without CsA could induce more TNF-α and IL-2 production by CD4 + T cells.
GAD-IN plus CsA vaccine prevents T1D in diabetic NOD mice
To examine if GAD-IN+CsA-induced pTregs protect mice from T1D progression, we vaccinated the 8-wk-old NOD model mice with 20 μg GAD-IN+CsA for three immunizations with 6-day intervals. Control mice were treated with mixed peptides alone, CsA alone or vehicle. The GAD-IN +CsA vaccinations prevented the development of T1D with over 70% of NOD mice from diabetes and remained diabetes-free to the end of this study. By contrast, only approximately 25% of those with CsA alone, or untreated controls remained diabetes-free (Figure 2a) . However, 95% of mice treated with mixed peptides without CsA had a more aggressive development of diabetes, indicating worsen autoimmunity by peptides alone. Consistently, fasting blood glucose levels were increased rapidly in the mice vaccinated with mixed peptides alone and vehicle, less aggressive with CsA alone, contrarily such level remained at normal range throughout the study in mice treated with the GAD-IN+CsA vaccine (Figure 2b ). Further analysis by oral glucose tolerance test (OGTT) was revealed that the NOD mice after GAD-IN+CsA vaccinations exhibited well glucose tolerance over a period of 150 min throughout the study whereas other control groups had less resistance in the same period ( Figure 2c ).
Islet lymphocytes infiltration causing insulitis hallmarks T1D. Thus, we next examined the islet tissues by section stained with hematoxylin and eosin (H&E) to reveal their structures and morphologies and rated the severity of destructions for insulitis by scoring the residual islets as insulitis, peri-insulitis, and no insulitis. As shown in Figure  2d and e, severity scores ranging from mild peri-insulitis to no insulitis were evaluated in the GAD-IN+CsA-vaccinated mice, whereas most of the mice immunized with mixed peptides alone, CsA alone or the vehicle exhibited more severe insulitis and less peri-insulitis with the small percentage of no insulitis. Immunohistochemical analysis showed that large numbers of CD4 + T cells were eliminated in pancreas after GAD-IN+CsA vaccination in T1D model mice (Figure 2f ), which may explain the diminished insulitis. Taken together, the combination of these islet-derived multipeptides formulated with CsA could suppress autoimmunity assault in mouse pancreas and prevent the onset of T1D effectively. Having demonstrated tolerogenic responses induced by the immunizations of GAD-IN+CsA vaccine in mice, we next sought to examine whether the protection from T1D after vaccination was due to an induction of tolerogenic DCs that foster naïve T cells into Tregs. To test this notion, we switched the GAD-IN peptides to the OVA 323-339 peptide since this OVA 323-339 has been extensively studied the nature of class II MHC-peptide binding and T-cell activation as a model antigen. 20, 21 We isolated splenic CD11c + DCs from BALB/c mice using magnetic beads to achieve >90% purity and stimulated with antigen OVA 323-339 with CsA at 1, 2.5, 5 or 10 μg/ml in vitro for 6 h, respectively, whereas the OVA 323-339 alone, or the vehicle served as controls. Levels of expression of anti-inflammatory cytokine IL-10 and co-stimulatory molecules CD40 and CD86 were assessed after the stimulation. The results revealed that DCs after such stimulation significantly displayed a "tolerogenic" status with increased expression of IL-10 and decreased expressions of CD40 and CD86 on the surface of DCs in a dose-dependent fashion when compared with the controls (Figures 3a-c and 2 ). The optimal dose that induced tolerogenic DCs was at 10 μg/ml CsA and 20 μg/ml OVA 323-339 peptide in vitro culture. − T cells into Tregs, we set up a co-culture system in which the DCs isolated from DO11.10 mice were in vitro stimulated with CsA and peptides for 4 h, followed by three times washes to remove any unbound substances. The treated DCs were then used to co-culture with CD4 + CD25
− T cells isolated from syngeneic DO11.10 mice for further 72 h. After this co-culture, we observed that co-cultured CD4 + CD25
− T cells were able to convert into more CD4
Tregs when compared with the controls (Figure 4a and c) . In addition to the conversion, we also observed that the Ki67 expression of these Tregs was significantly higher when further stimulated with cognate antigen in vitro when compared with other groups (Figure 4a and c) . The data suggested that CsA plus antigen could induce tolerogenic DCs in vitro and lead to cocultured naïve T cells switching into antigen recognized and expandable Tregs. More importantly, the induced Tregs, taken from the induction system described above, could suppress the proliferation of OVA primed CD4 + CD25 + Foxp3 − Teff cells isolated from OVA immunized DO11.10 mice when co-cultured with the Treg cells (Figure 4d-e) . We further examined cytokine expressions from these Teff cells in such co-culture system to determine whether the cytokine profiles were also changed. The expression levels of IFN-γ, TNF-α, and IL-2 were significantly down-regulated when primed Teff cells were co-cultured with Tregs from the previous fostered with OVA 323-339 + CsA treated DCs compared with other conditions (Figure 4f-h) . These results indicated that OVA 323-339 + CsA-induced tolDCs could promote the expandable and functional CD4 +
Foxp3
+ Tregs, resulting in the suppression of proliferation and functions of Teff cells in vitro.
Discussion
Strategies of inducing antigen-specific tolerance to prevent T1D have been reported in the NOD animal model, but few translated into bedside successfully. 2, 3, 22 Although induction of antigen-specific pTregs has been considered as a safe and effective means to control T1D, it is a challenge to induce such antigen-specific pTregs by vaccination. In this study, we demonstrated that immunization of islet-derived multipeptides plus CsA (GAD-IN+CsA vaccine) in prediabetic NOD mice could induce a tolerogenic response against the Several recent approaches targeted to induce immunotolerance against T1D have been tried in clinical settings with limited success. 23, 24 Since Tregs are the most important immunotolerance player to regulate over inflammatory responses, which is potentially harmful to host, aiming to induce Tregs ex vivo or in vivo becomes an overt and favorable choice although it still has numerous technical challenges to be solved. Among them, ex vivo expansion of nTregs as an individualizing medicine can be given to patients with T1D by adoptive transfer of autologous expanded cells had advantages over other methods since it only required fewer manufacture processes and tests as a novel drug does. 25, 26 However, no significant improvements were observed for C-peptide as well as metabolic functions of these treated patients. 27 Despite the fact of earlier failures in several clinical trials, ex vivo for antigen-specific Tregs induction technical has been tried and tested in clinical trials. 22, 28 Those improved ex vivo strategies may further be proved the importance of Tregs in maintaining of immunotolerance for treating T1D.
Alternatively, the use of autoantigen(s)-based therapeutic vaccine has greater impacts on the treatment of patients with T1D. Once it has been proved to be effective, all patients with T1D will theoretically benefit from long-term administration of immunosuppressant. However, such promised strategies had not been efficacious in human since several clinical trials by using this type of approaches were not successfully reproduced in patients with T1D. For example, a vaccine based on the GAD65 formulated in alum adjuvant was given 219 patients with T1D in one clinical trial but ineffective with neither improvement of C-peptide nor controlling the blood glucose level over 15 months. 29 Another vaccine comprised of the insulin B-chain peptide formulated in Incomplete Freund's adjuvant (IFA) given to patients with T1D has exhibited Treg cells responses but no C-peptide improvements. 30 Several similar antigen peptide or peptides based on insulin B chain or A chain without adjuvant have also been tried in clinical settings. No relief hypoglycemia was achieved, although some treated patients with T1D were responded to vaccinations with fluctuations of IL-10 levels, suggesting some degrees of induction of immunotolerance. 31, 32 Other approaches including the BCG immunizations intended to induce re-balanced immunity has also exhibited some degree of hyperglycemia improvement with elevating frequency of Tregs although its mechanism of action is still elusive. 33 Vaccines mentioned above had less efficient to induce desire high potential antigen-specific pTregs in patients despite facts these can be effective to treat T1D in animal models. Although the induction of potent antigen-specific pTregs had many approaches, auto-antigen itself is insufficient to do so since it often induces stronger autoimmune response or non-response. Adjuvants should be considered in designing a tolerogenic vaccine. Adjuvant containing Alum or IFA could help an antigen to induce Th2 biased response, but not favorable to promote the tolerogenic response. Other types of adjuvants facilitating to induce immunotolerance must be taken into consideration.
CsA is a widely used immunosuppressant against allograft rejections or treating various autoimmune diseases, such as rheumatoid arthritis, T1D, and psoriasis. [34] [35] [36] [37] CsA typically binds to the cyclophilin of immune cells and prevents the activation of T cells by inhibiting the transcription factor nuclear factor of activated-T cells (NFATc) signaling. 38 Previous studies have demonstrated that CsA also has a modulating effect on innate immune cells, including natural killer (NK) cell, macrophage, and DC. [39] [40] [41] [42] Those suggested that CsA could modulate DCs and affect outcomes of T cells. As our previous studies reported that the vaccine employing one immunosuppressant dexamethasone as adjuvant could induce a higher number of IL-10 producing immature DCs and in turn to induce expandable antigen-specific pTregs. 43 In this study, we showed that islet-derived multipeptides plus CsA could induce a higher level of antigen-specific pTregs control the blood glucose with less insulitis in NOD animal model. This type of pTregs induction could also be achieved using peptides plus CsA treated DCs in vitro. The immature IL-10 hi CD40 lo phenotype of DCs was generated through antigen plus CsA treatment in a dose-dependent manner in vitro. Although the mechanism of induction of pTreg cell by immature or tolerogenic DC is complicated, the molecular mechanisms have been documented previously. It may rely on the secretion of IL-10 or IDO, expression of programmed cell death ligands 1 (PD-L1) from tolerogenic DC to influence naïve T cell differentiation during DC-T antigen presentation. 13, 44, 45 Several independent studies have shown that a T cell with a regulatory phenotype can be induced through interacting with antigen-pulsed tolerogenic DCs treated with vitamin D3, rapamycin, aspirin, or simvastatin. [46] [47] [48] [49] In agreement of these pieces of evidence, the CsA plus antigen in vitro treatments could greatly modulate the process of DC maturation, and programs DCs to a tolerogenic state, which lead to pTregs induction.
However, the exact mechanism of tolerogenic DCs induced by CsA plus autoantigens still needs to be further explored. Both CD4 + and CD8 + T cell can play highly pathogenic roles in the development of T1D. The evaluation of inhibitory effect on CD8 + T cell after immunization with islet-derived multipeptides plus CsA (GAD-IN+CsA vaccine) should be conducted as well. Since islet autoantigenic peptides GAD65 206-220 , GAD65 536-550 , Insulin B [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] , and Insulin C 17 -A 1 as applied in this study are epitopes recognized by CD4 + T cells both in NOD mice and patient with T1D. 50, 51 It could be readily adaptable for a clinical development once demonstrated its efficacy in NOD mice. Furthermore, the optimal effective dose for inducing tolerance and the safety in human are remained as ambiguous and challenging. In summary, the experiments described in this paper showed that islet-derived multipeptides with CsA as a composition to induce tolDCs and in turn to foster expandable antigen-specific pTregs to suppress auto-reactive Teff cells effectively, in resulting a prevent T1D onset in NOD animals. This antigen-specific pTregs induction, in conjunction with our previous studies, ingeminates the role of tolerogenic adjuvant by using immunosuppressants in the modulation of the tolDCs-Tregs process. Due to such strategy adaptable for clinical development, this vaccine might promote clinical application to treat patients with T1D in the future.
Materials and methods
Animals and reagents
Adult female BALB/c mice (6-8 wks of age) were purchased from the Shanghai SLAC Laboratory Animal Co. Ltd. (Shanghai, China). Male NOD mice (6-8 wk old) were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China). DO11.10 OVA-specific TCR-transgenic BALB/c mice were gifts from Dr. Shi Yan (Tsinghua University, Beijing, China). They were bred and housed under pathogen-free conditions, and all animal protocols were approved by the Animal Welfare Committee of Fudan University. Streptozocin (STZ), lipopolysaccharide (LPS) were all purchased from Sigma Aldrich (St Louis, MO, USA). Cyclosporin A (CsA) was purchased from Fujiang Kerui Parhmarceutic Co. LTD (Fujiang, China). Peptides were all synthesized by Shanghai Science Peptide Biological Technology Co. Ltd (Shanghai, China) with the purity higher than 95%.
Vaccine preparation, immunization, and diabetes monitoring
Four of CD4 epitopic peptides were selected based on previous reports as immunogens for this study, including 
Foxp3
− effector T cells were isolated from spleen and pancreatic lymph node and analyzed by Flow cytometry. Blood glucose level was assessed by Yicheng JPS-6 Glucometer with glucose test strips (Yicheng Bioelectronics Technology Company, Beijing, China) every 3 days. Mice with two consecutive blood glucose levels of ≥15 mmol/l were defined as the onset of diabetes.
Oral glucose tolerance test (OGTT)
All immunized or control NOD mice, which were taken from 30 days after the first vaccination, were orally administered glucose at a dose of 2 g/kg body weight following an overnight fast. Blood samples were obtained at time 0, 30, 60, 120, and 150 min after the glucose administration and used to measure glucose levels with glucose test strips.
Histopathology
On day 30 after the first immunization, the pancreas was fixed in formalin, embedded in paraffin, sectioned and stained with hematoxylin and eosin (H&E). Sections were analyzed under a light microscope to determine histological changes. Paraffinembedded pancreas sections were used for CD4 immunostaining with purified anti-mouse CD4 antibody (Cell Signaling Technology, USA).
In vitro stimulation of purified DCs
DCs were purified from 6-wk-old female BALB/c and DO11.10 mice. In brief, single-cell suspensions were obtained from freshly isolated spleen tissues and used to incubate with anti-mouse CD11c-coated magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) at room temperature for 30 min followed with purification through MACS separation columns. The purity of DCs assessed over 90% by FACS. DCs were plated in 96-well plates at 1 × 10 5 cells/ml in R-10 medium (RPMI 1640/10% heat-inactivated fetal bovine serum) with either CsA (1, 2.5, 5 or 10 μg/ml) and 20 μg/ml OVA 323-339 mixture, 20 μg/ml OVA 323-339 peptide alone, 100 ng/ml LPS, or vehicle, respectively. After 6 h in vitro culture, the cells were washed in PBS three times to remove unbound substances and fraction of them were used for phenotype analysis, and the remained portions were further used for co-culture assay.
Phenotype analysis of DCs
After treatment with the different stimulus, isolated DCs were stained with specific mAb for phenotype analysis. Briefly, DCs (1 × 10 5 ) were incubated in FACS buffer (2% fetal bovine serum in PBS) at 4°C for 30 min along with surface costimulatory molecule mAbs and viability dye, measured by flow cytometry and analyzed as the median fluorescence intensity (MFI). For intracellular anti-inflammatory cytokine, cells were fixed in 1% paraformaldehyde (Sigma, St. Louis, MO, USA), permeabilized with 0.5% Tween 20 and intracellularly immunostained as described. 43 Anti-inflammatory cytokine-producing DCs were quantified relative to total CD11c + DCs. Fixable viability dye eFlour780 (Biolegend, San Diego, CA, USA) was used to exclude dead cells following its staining protocol. 5 per well in a 96-well plate and further treated with 20 μg/ml OVA 323-339 plus 10 μg/ml CsA, OVA 323-339 alone, CsA alone, or vehicle in RPMI medium for 4 h in vitro, and followed by washing away free stimulants with fresh medium for three times. Naïve For Such pretreated DCs were cocultured at 1:10 ratio with the CD4 + CD25
− T cells from DO11.10 transgenic mice previously immunized once with 10 μg of OVA protein in aluminum adjuvant and sorted by BD Aria II sorter (BD Bioscience, San Diego, CA, USA) supplied with 100 U/ml recombinant IL-2 (Biolegend). Anti-CD3 (2 μg/ml) and anti-CD 28 (2 μg/ml) antibodies in the presence of 100 U/ml recombinant IL-2 and 0.5 ng/ml TGF-β (Biolegend) were used to induce Tregs from Naïve T cells served as quality control. After co-cultured for 72 h, CD4 + T cells were collected and washed in PBS. The percentage of Tregs and expression of Ki67 on these cells were analyzed by the flow cytometry, gated on live CD11c 
Foxp3
− relative to total CD4 + T cells and intracellular staining of Ki67. Functional cytokines IFN-γ, IL-2 and TNF-α of Teff cell were also detected after adding protein transport inhibitor BD GolgiPlug™ (Brefeldin A) (BD Bioscience) at last 6 h. Naïve T cells were activated with coated anti-CD3 and anti-CD28 antibodies plus cytokines IL-2 for 3 days, and then stimulated with Phorbol 12-Myristate 13-Acetate (PMA) (Sigma, St. Louis, MO, USA) and a calcium ionophore (Ionomycin) (Sigma, St. Louis, MO, USA) for last 6 h as positive control for these cytokines detection.
Flow cytometry
The phenotypes of sorted DCs and T cells from pancreatic lymph nodes were analyzed by FACS FORTESSA with Diva software (BD Bioscience). Cells were stained with the following surface Abs: CD11c FITC (BD Bioscience), CD40 PerCP-Cy5.5 (eBioscience, USA), CD86 APC (eBioscience, USA), CD4 APC (eBioscience, USA) and CD25 (eBioscience, USA) Abs and incubated at 4°C for 30 min. For intracellular analysis of Foxp3 PE (eBioscience, USA), ki67 QD605 (Biolegend, San Diego, CA, USA), IL-10 BV421 (Biolegend, San Diego, CA, USA) and TGF-β PerCP-Cy5.5 (Biolegend, San Diego, CA, USA) expression, cells were stained with Foxp3 staining buffer according to the manufacturer's protocol (eBioscience, USA). For intracellular cytokine IL-2 Brilliant violet 421 (Biolegend, San Diego, CA, USA), IFNγ PE-Cy7 (eBioscience, USA) and TNFα PE (eBioscience, USA) staining, T cells isolated from DO11.10 mice were treated with Brefeldin A for 6 h. After coculture, cells were washed in FACS buffer, fixed in 1% paraformaldehyde, permeabilized with 0.5% Tween 20, and stained with intracellular cytokine mAbs at 4°C for 40 min.
Statistical analysis
Data were analyzed using Prism 6 software (GraphPad Software, La Jolla, CA, USA) by either Student t-test (column analyses) or one-way ANOVA. The p values < 0.05 were considered significant.
